Wolverine Trading’s Anika Therapeutics ANIK Stock Holding History

Wolverine Trading’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,700	Closed	-$215K	–	4820
2017 Q3	$215K	Buy	+3,700	New	+$193K	﹤0.01%	3708

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's ANIK Position: Q4 2017 in Review

Wolverine Trading sold out of Anika Therapeutics (ANIK) in Q4 2017, closing a stake of 3,896 shares — an estimated $226K sold.

Wolverine Trading first reported a position in ANIK in Q3 2017 and held it in 1 quarter. The position peaked at $226K in Q3 2017. 172 funds tracked by Wall St. Rank hold ANIK as of Q4 2017.

Wolverine Trading reported no remaining Anika Therapeutics position as of Q4 2017 after selling out during the quarter.
Wolverine Trading sold 3,896 Anika Therapeutics shares in Q4 2017, an estimated $226K.
Wolverine Trading first reported a position in Anika Therapeutics in Q3 2017 and held it in 1 quarter.
Wolverine Trading's Anika Therapeutics position peaked at $226K in Q3 2017.
172 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2017.

Based on Wolverine Trading's 13F filing for Q4 2017, filed 14 Feb 2018.